300 related articles for article (PubMed ID: 25590805)
21. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
22. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
[TBL] [Abstract][Full Text] [Related]
23. Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells.
Shiraishi N; Onda T; Hayashi K; Onidani K; Watanabe K; Sekikawa S; Shibahara T
Oncol Rep; 2021 Feb; 45(2):448-458. PubMed ID: 33416122
[TBL] [Abstract][Full Text] [Related]
24. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
[TBL] [Abstract][Full Text] [Related]
25. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression.
Liu H; Lu Z; Shi X; Liu L; Zhang P; Golemis EA; Tu Z
J Biol Chem; 2021 Aug; 297(2):100996. PubMed ID: 34302809
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
27. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
[TBL] [Abstract][Full Text] [Related]
28. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
29. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
[TBL] [Abstract][Full Text] [Related]
31. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
32. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M
Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794
[TBL] [Abstract][Full Text] [Related]
33. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
[TBL] [Abstract][Full Text] [Related]
34. FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.
Ye M; Huang W; Wu WW; Liu Y; Ye SN; Xu JH
Oncotarget; 2017 Feb; 8(9):15364-15376. PubMed ID: 28157708
[TBL] [Abstract][Full Text] [Related]
35. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
36. Ganetespib radiosensitization for liver cancer therapy.
Chettiar ST; Malek R; Annadanam A; Nugent KM; Kato Y; Wang H; Cades JA; Taparra K; Belcaid Z; Ballew M; Manmiller S; Proia D; Lim M; Anders RA; Herman JM; Tran PT
Cancer Biol Ther; 2016 Apr; 17(4):457-66. PubMed ID: 26980196
[TBL] [Abstract][Full Text] [Related]
37. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
[TBL] [Abstract][Full Text] [Related]
38. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
[TBL] [Abstract][Full Text] [Related]
39. Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest.
Ren M; Zhou X; Gu M; Jiao W; Yu M; Wang Y; Liu S; Yang J; Ji F
Oncol Rep; 2020 Oct; 44(4):1605-1615. PubMed ID: 32945472
[TBL] [Abstract][Full Text] [Related]
40. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Giubellino A; Sourbier C; Lee MJ; Scroggins B; Bullova P; Landau M; Ying W; Neckers L; Trepel JB; Pacak K
PLoS One; 2013; 8(2):e56083. PubMed ID: 23457505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
